Invited commentary: Pretreatment with dextran 1 makes dextran 40 therapy safer

Parenteral iron dextran therapy.

Parenteral iron therapy is indicated in patients with iron-deficiency anemia associated with conditions that interfere with the ingestion or absorption of oral iron. Replacement doses of iron required to replenish iron stores are based on body weight and the observed hemoglobin value. Methods of administering iron dextran are reviewed, including intramuscular and intravenous injections of the u...

Effect of Dextran 40 on Urine Flow

Dextran 40: another cause of drug-induced noncardiogenic pulmonary edema.

Drug-induced noncardiogenic pulmonary edema occurred in a previously patient receiving dextran 40. Dextran 40 should be considered another etiologic factor of drug-induced noncardiogenic pulmonary edema when this syndrome occurs in the absence of known precipitating causes such as shock, aspiration, and overwhelming pneumonia.

Utilization of iron dextran.

The utilization of iron dextran was investigated in normal subjects, in patients with iron-deficiency anaemia, and in anaemias associated with rheumatoid arthritis, reticulosis, and uraemia. Utilization of iron for haemoglobin formation at 14 days was found to be depressed in patients with rheumatoid arthritis, reticulosis, and uraemia, but when a concomitant iron-deficiency anaemia was present...

Enzymatic synthesis of dextran.

Dextran, a glucose polymer composed predominantly of ol-1,6-glucopyranosidic linkages, is produced from sucrose by Leuconostoc mesenteroides and related organisms and from dextrins by other bacteria (see the review by Hehre (1)). Conversion of sucrose to dextran is catalyzed by an enzyme, dextransucrase, elaborated by the organisms. Dextransucrase preparations as culture filtrates (2, 3) or as ...